ARS Pharmaceuticals, Inc. SPRY Current ratio

Current ratio at other companies

Aquestive Therapeutics, Inc.AQST

4.1×-0.8×

Amneal Pharmaceuticals, Inc.AMRX

2.2×+0.8×

ViatrisVTRS

1.6×+0.2×

AMP

Amphastar PharmaceuticalsAMPH

2.4×-0.9×

Neuropace, Inc.NPCE

5.4×-1.2×

Eton Pharmaceuticals, Inc.ETON

1.2×-0.8×

FAQ

What is ARS Pharmaceuticals, Inc.'s current ratio?

ARS Pharmaceuticals, Inc. (SPRY) reported current ratio of 4.9× in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s current ratio changed year-over-year?

ARS Pharmaceuticals, Inc.'s current ratio decreased by 55.1% year-over-year, from 11× to 4.9×.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s current ratio?

Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s current ratio has grown at a -29.1% compound annual growth rate (CAGR), from 40.7× to 7.3×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.